Gsk (GSK) Receivables - Other (2016 - 2025)

Gsk (GSK) has 10 years of Receivables - Other data on file, last reported at $1.5 billion in Q4 2025.

• In Q4 2025, Receivables - Other rose 38.7% year-over-year to $1.5 billion; the TTM figure through Dec 2025 stood at $1.5 billion (up 38.7% YoY), while the FY2025 annual figure was $1.5 billion, up 38.7% from the prior year.
• Receivables - Other improved to $1.5 billion in Q4 2025, from $1.1 billion in the prior quarter.
• Across five years, Receivables - Other topped out at $1.7 billion in Q4 2021 and bottomed at $1.1 billion in Q4 2024.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other slipped 15.74% — and 2025, when it soared 38.7%.
• Year by year, Receivables - Other stood at $1.7 billion in 2021, then declined by 15.74% to $1.4 billion in 2022, then retreated by 9.81% to $1.3 billion in 2023, then decreased by 15.19% to $1.1 billion in 2024, then jumped by 38.7% to $1.5 billion in 2025.
• The last three Receivables - Other figures came in at $1.5 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.3 billion (Q4 2023), per Business Quant data.

Peer Comparison